WuXi Bio seeks green light for $300m Hong Kong listing

John Loh,

Jonathan Breen

May 11, 2017 12:00 pm

WuXi BioLogics, which is planning a $200m-$300m IPO in Hong Kong, is set to begin investor education next week if the stock exchange grants it approval at a listing hearing on May 15, said a banker close to the deal.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

Equity IPOs China Merchants Securities Co Equity Bank of America Hong Kong SAR Asia Greater China Morgan Stanley Northeast Asia BNP Paribas Asia Pacific Emerging Markets HSBC

JL

John Loh

JB

Jonathan Breen

Equities editor GlobalCapital Asia